Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New progestagens for contraceptive use.

Regine Sitruk-Ware1

  • 1Rockefeller University and Population Council, New York, NY, USA. regine@popbc.rockefeller.edu

Human Reproduction Update
|November 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low dose intranasal nestorone self-emulsifying drug delivery system promotes neuroprotection in experimental stroke through modulation of glial cells.

Drug delivery and translational research·2026
Same author

Contraception today and family planning: a comprehensive review and position statement on the ethical, medical, and social dimensions of modern contraception.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2025
Same author

Optimized intranasal delivery of segesterone acetate progestin to the brain using nanoemulsions and microemulsions.

Drug delivery and translational research·2025
Same author

Tribute to Prof. Eberhard Nieschlag.

Contraception·2025
Same author

Consensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials.

Contraception·2025
Same author

Development of a transdermal gel for reversible male contraception.

Contraception·2025

New progestins offer improved selectivity and reduced side effects compared to older hormonal contraceptives. These advanced progestins aim for reduced androgenic and estrogenic activity, potentially offering safer metabolic profiles.

Area of Science:

  • Pharmacology and Endocrinology
  • Reproductive Health
  • Drug Development

Background:

  • Progestins are key components in hormonal contraceptives, primarily for ovulation suppression, often combined with ethinyl-estradiol (EE).
  • Structural modifications of parent molecules like testosterone or progesterone (P) significantly alter progestin activity.
  • Developing progestins with improved selectivity and fewer side effects has been a major research focus.

Purpose of the Study:

  • To review the pharmacological properties of newer generation progestins.
  • To compare the antiovulatory potency and side effect profiles of various progestins.
  • To evaluate the potential metabolic and vascular effects of novel progestins.

Main Methods:

  • Review of pharmacological data on synthesized progestins, including dienogest (DNG), drospirenone (DRSP), Nestorone (NES), nomegestrol acetate (NOMAc), and trimegestone (TMG).

Related Experiment Videos

  • Comparison of antiovulatory potency and androgenic/estrogenic activity.
  • Analysis of reported side effects and potential interactions with ethinyl-estradiol (EE).

    • Main Results:

    • Newer progestins like TMG and NES exhibit high antiovulatory potency, surpassing older agents like levonorgestrel (LNG).
    • DNG, DRSP, and TMG possess antiandrogenic activity, while DRSP also has antimineralocorticoid properties.
    • Progestins derived from 19-norprogesterone, such as DRSP and DNG, are non-androgenic and do not negatively impact lipid profiles.

    Conclusions:

    • Novel progestins demonstrate improved pharmacological profiles, including enhanced selectivity and reduced androgenic effects.
    • These newer agents may offer a more favorable side effect profile and potentially neutral metabolic and vascular risk.
    • Further large-scale clinical trials are necessary to confirm the long-term safety and efficacy of these advanced progestins.